Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Bekaii-Saab TS, Melisi D, Wilmink H, Garufi C, Tran N, Tortora G, De Braud F, Frodin JE, Lonardi S, Lin E, Babiker H, Lin B, Fornaro L, Muñoz Martín A, Bridgewater J, Knox JJ, De Vos-Geelen J, Scott-Brown M, Veronese L, Ioannidis S, Gilmartin A, Janik JE, Guo Y, Furuse J, Ioka T, Rimassa L, Vogel A

Open source

DOI: 10.1200/jco-26-00788
Published: 2026 Aug 10
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-26-00788,
  title = {Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.},
  author = {Bekaii-Saab TS and Melisi D and Wilmink H and Garufi C and Tran N and Tortora G and De Braud F and Frodin JE and Lonardi S and Lin E and Babiker H and Lin B and Fornaro L and Muñoz Martín A and Bridgewater J and Knox JJ and De Vos-Geelen J and Scott-Brown M and Veronese L and Ioannidis S and Gilmartin A and Janik JE and Guo Y and Furuse J and Ioka T and Rimassa L and Vogel A},
  year = {2026},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-26-00788},
  url = {https://doi.org/10.1200/jco-26-00788}
}

RIS

TY  - JOUR
TI  - Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.
AU  - Bekaii-Saab TS
AU  - Melisi D
AU  - Wilmink H
AU  - Garufi C
AU  - Tran N
AU  - Tortora G
AU  - De Braud F
AU  - Frodin JE
AU  - Lonardi S
AU  - Lin E
AU  - Babiker H
AU  - Lin B
AU  - Fornaro L
AU  - Muñoz Martín A
AU  - Bridgewater J
AU  - Knox JJ
AU  - De Vos-Geelen J
AU  - Scott-Brown M
AU  - Veronese L
AU  - Ioannidis S
AU  - Gilmartin A
AU  - Janik JE
AU  - Guo Y
AU  - Furuse J
AU  - Ioka T
AU  - Rimassa L
AU  - Vogel A
PY  - 2026
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-26-00788
UR  - https://doi.org/10.1200/jco-26-00788
ER  -

APA

TS, B., D, M., H, W., C, G., N, T., G, T., F, D. B., JE, F., S, L., E, L., H, B., B, L., L, F., A, M. M., J, B., JJ, K., J, D. V., M, S., L, V., S, I., A, G., JE, J., Y, G., J, F., T, I., L, R., & A, V. (2026). Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-26-00788

Source records

pubmed · retrieved 2026-09-26T04:58:14.340Z